about
The Fbw7 tumor suppressor regulates nuclear factor E2-related factor 1 transcription factor turnover through proteasome-mediated proteolysisFBXW7 mutations typically found in human cancers are distinct from null alleles and disrupt lung developmentInvestigation of the atypical FBXW7 mutation spectrum in human tumours by conditional expression of a heterozygous propellor tip missense allele in the mouse intestinesMutation analysis of hCDC4 in AML cells identifies a new intronic polymorphism.Aberrant regulation of FBW7 in cancer.Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancerMYC cofactors: molecular switches controlling diverse biological outcomes.Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia.MiR-25 regulates Wwp2 and Fbxw7 and promotes reprogramming of mouse fibroblast cells to iPSCs.Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins.Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cellsProtein ubiquitination in lymphoid malignancies.MicroRNA-27a distinguishes glioblastoma multiforme from diffuse and anaplastic astrocytomas and has prognostic valueCombined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cellsBalance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-MycSCF Fbx4/alphaB-crystallin cyclin D1 ubiquitin ligase: a license to destroy.Fbw7/hCDC4 dimerization regulates its substrate interactionsIt is not all about BRCA: Cullin-Ring ubiquitin Ligases in ovarian cancer.Dual regulation of notch1 signaling pathway by adaptor protein fe65FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC.Integrin-linked kinase controls Notch1 signaling by down-regulation of protein stability through Fbw7 ubiquitin ligaseGSK-3β regulates cell growth, migration, and angiogenesis via Fbw7 and USP28-dependent degradation of HIF-1αThe two faces of FBW7 in cancer drug resistance.The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis.Phosphorylation-dependent regulation of Notch1 signaling: the fulcrum of Notch1 signaling.SAG/ROC2 E3 ligase regulates skin carcinogenesis by stage-dependent targeting of c-Jun/AP1 and IkappaB-alpha/NF-kappaB.FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitorsFBXW7 is involved in Aurora B degradation.HER2-Akt signaling in regulating COP9 signalsome subunit 6 and p53The ins and outs of MYC regulation by posttranslational mechanisms.Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers.Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target.Study of single nucleotide polymorphisms of FBW7 and its substrate genes revealed a predictive factor for paclitaxel plus cisplatin chemotherapy in Chinese patients with advanced esophageal squamous cell carcinoma.The role of NOTCH1 signaling in T-ALL.Role of Notch signaling pathway in pancreatic cancer.Autophagy negatively regulates tumor cell proliferation through phosphorylation dependent degradation of the Notch1 intracellular domain.Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia.MYC degradationUbiquitination involved enzymes and cancer.
P2860
Q28249259-040A2FDB-C8E6-4436-A497-3733BEA83185Q28590336-1CCE70B6-636E-4BF4-88FE-946524EBFCF1Q28658581-C82FB717-4139-4394-A202-F95B67C85F31Q33262849-FED96BFD-7B3E-4CA2-99DE-10647DCD6505Q33688508-93D4BFD5-2FDB-4B1E-8FC6-8BC4909044EAQ33976883-A721040C-0C5A-4A01-A4CC-67B5755AF991Q34083178-C04A0F28-E205-488D-80F7-89B37F468E63Q34151863-46342797-07BD-4326-A15F-4F67BE7BA3E7Q34388582-F6898A17-7DC8-4063-9B82-28B6F0C1D323Q34610662-4EE549B9-49ED-4C5C-B642-7751617547A6Q34619655-2CB8014A-F693-4C47-8C44-A9179C07575BQ34722684-C71D59CC-E8AC-44F9-B31C-84ED4748B5FBQ34991208-22E0A598-FA21-4116-A4E0-08F554EE378EQ34994576-43E07DFB-3F7D-44ED-B093-FA9B0CB0E044Q35082715-E3D8FEE0-C8C5-4A20-BAE3-35B9249E4B0EQ35622873-505A4278-C663-4821-884F-F483782BA7BBQ35647016-53DD6B51-846D-4D47-8C04-94E043F4D70DQ35678132-DBAE4CCA-9E22-4707-BC25-6B912FB41143Q35763040-97403903-95CD-4E2C-922E-48F8BA6B8E6BQ35828658-59B349E5-A7DC-4168-BE1D-91E3376BC707Q35950088-7F6CCAB3-6506-43A1-979A-2237118C2F7EQ35959502-4287E143-B92A-4B57-B511-4AE287EB1028Q35999467-66195460-DA71-4410-AC9A-470A64FBE9CCQ36029051-C80445E3-3E3E-4DD0-A1B8-4A2E59D0A317Q36078480-0C27B413-7379-42AD-A911-B2B309F75D7AQ36119281-433627A1-A3A3-4088-AF0E-DAF4BAB3FEB0Q36229551-F4C77D29-F281-4B74-BD16-90A9454CF0C3Q36426514-3AEBDE4F-00FE-4F01-A6C7-9BE6F7A4E9F2Q36472246-6CE91377-CE43-4442-B740-832F96BE4D1CQ36599161-7E6BAA59-C9FC-4439-8539-B5DBDE58BC27Q36699782-9F665AF7-7EF3-4A4A-8EB7-687277EA9420Q37272977-07C25B58-84AD-44F4-B55C-1CD3F5B6E283Q37486782-67E0B114-5BFE-40D1-BC68-33E8E6C998D7Q37536887-C52E90C1-8850-483C-A5A9-46A66C0BF3F1Q37653228-4FCBD239-02F4-4783-AC74-E6C2F5B51D68Q37679979-866C19CE-F9E8-41D2-B4D5-4BE98EBC2914Q37694748-8786990A-CF28-43FD-9DA3-DE6DCC3004D6Q37802059-E4B02545-5ED6-4FCA-BB30-5F94065AAC37Q38193043-967C2D0A-0851-4A4E-872C-C16C5372E2B6Q38229325-3F95DACA-0B99-41BD-8CB1-5D1DB4965990
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Mechanisms of tumor suppression by the SCF(Fbw7).
@ast
Mechanisms of tumor suppression by the SCF(Fbw7).
@en
type
label
Mechanisms of tumor suppression by the SCF(Fbw7).
@ast
Mechanisms of tumor suppression by the SCF(Fbw7).
@en
prefLabel
Mechanisms of tumor suppression by the SCF(Fbw7).
@ast
Mechanisms of tumor suppression by the SCF(Fbw7).
@en
P356
P1433
P1476
Mechanisms of tumor suppression by the SCF(Fbw7).
@en
P2093
Alex C Minella
Bruce E Clurman
P304
P356
10.4161/CC.4.10.2058
P577
2005-10-27T00:00:00Z